Medical (incl. medical device & pharma), US Foreign Corrupt Practices Act & Dodd Frank - Written by on Tuesday, November 23, 2010 3:23 - 0 Comments

Pharmaceutical businesses and the stark warning from the SFO

Print Friendly

Barry and Richard write on FCPA Compliance and Ethics Blog about the thinly veiled warning recently issued by the Director of the Serious Fraud Office, Richard Alderman to the pharmaceutical sector.

It has been well publicised that the pharmaceutical sector has been under increasing scrutiny from US regulators. Mr. Alderman spoke at a UK pharmaceutical conference about the industry, the Bribery Act and the SFO’s close co-operation with the US Department of Justice which is involved in a Foreign Corrupt Practices Act investigation into the pharmaceutical sector in the US.

Share Button


Comments are closed.

Brought to you by...

Barry Vitou &
Richard Kovalevsky Q.C.

The views expressed on this website are those of Barry Vitou & Richard Kovalevsky QC and/or our guest authors from time to time. Please see our terms of use

Our Tweets

Wednesday, May 22, 2019 15:03

Dawn raids, searches & media enquiries our top 5 tips and what they have in common with fires.https://t.co/hIV96Jh1JM

Saturday, May 18, 2019 14:27

BBC News - Austria minister Heinz-Christian Strache resigns amid video scandal https://t.co/8OrgfB70J7

Sunday, May 12, 2019 18:41

Very sad to hear the news about Brian Walden. I loved Weekend World not so long ago I was interrogated by him for… https://t.co/4yYKXGjj7X